Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Tryp Therapeutics Inc (TRYP.CN)

Tryp Therapeutics Inc (TRYP.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stocks in play: Tryp Therapeutics Inc

Today announced the filing of two new provisional patent applications. One patent application, #63/405,786, ...

TRYP.CN : 0.160 (unch)
TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

/CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based...

TRYP.CN : 0.160 (unch)
TRYPF : 0.1200 (unch)
Stocks in play: Tryp Therapeutics Inc

Announced a non-brokered private placement to its co-Founder and Executive Director, William J. Garner, ...

TRYP.CN : 0.160 (unch)
Stocks in play: Tryp Therapeutics Inc

Announced today that it has received confirmation from the U.S. Food and Drug Administration that its ...

TRYP.CN : 0.160 (unch)
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration...

TRYP.CN : 0.160 (unch)
TRYPF : 0.1200 (unch)
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Clinical Trials, Focus Puts It ‘In Pretty Rarefied Air’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)  is advancing toward the launch of four phase 2a studies of its two novel drug candidates, TRP-8802 and TRP-8803, for treating fibromyalgia, phantom limb pain,...

TRYP.CN : 0.160 (unch)
TRYPF : 0.1200 (unch)
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways

Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass...

ATAI : 3.24 (-6.36%)
CMPS : 11.19 (-4.20%)
TRYP.CN : 0.160 (unch)
TRYPF : 0.1200 (unch)
FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process

Psychedelic drug medical research firm Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has received final U.S. Food and Drug Administration (“FDA”) approval to get under way with its planned clinical...

TRYP.CN : 0.160 (unch)
TRYPF : 0.1200 (unch)
Missed Eating Disorder Diagnoses in Men Are on the Rise

Eating disorders are severe mental and physical illnesses that encompass  damaging relationships with  body image, exercise, eating and food. Research has found that behaviors that are linked to eating...

TRYP.CN : 0.160 (unch)
TRYPF : 0.1200 (unch)
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the...

TRYP.CN : 0.160 (unch)
TRYPF : 0.1200 (unch)

Barchart Exclusives

Broadcom Stock Is Cheap, Selling Below Its Historical Averages
Broadcom stock trades well below its historical averages for dividend yield and price-to-earnings. Moreover, the company is doing large buybacks. These factors make it attractive to value buyers. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar